Ligand’s partner Jazz Pharmaceuticals receives EC approval for Enrylaze

Ligand Pharmaceuticals (LGND) announced that its partner Jazz Pharmaceuticals plc (JAZZ) has been granted marketing authorization by the European Commission, EC, for Enrylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. “We congratulate our partner Jazz on its receipt of approval for Enrylaze from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals. “Jazz has executed on a successful launch of the product in the U.S., and we look forward to contributions from sales in the European Union.” Ligand is eligible to receive milestone payments and tiered low- to mid-single digit royalties based on worldwide net sales of any products resulting from its collaboration with Jazz, including Rylaze.